Equity · Healthcare
EYPT
NASDAQEyePoint Pharmaceuticals (EYPT)
The line runs 13.49 USD on 13 August through 4 USD on 18 September, on a scale from 0 to 15. Days the market did not trade hold the previous close, flat.
- Market cap
- 344.8M USD
- Revenue, year to Dec 2025
- 31.4M USD
- EPS, diluted, year to Dec 2025
- −3.17 USD
- Avg volume
- 283.8K
as of Sep 18, 2026
Have EyePoint Pharmaceuticals (EYPT) insiders bought or sold shares recently?
In the 90 days to 11 Nov 2026, EyePoint Pharmaceuticals insiders reported 1 open-market purchase and no sales (SEC Form 4).
Form 4, 90 days to 11 Nov 2026, newest reported trade 18 Aug 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 18 Aug 2026 | Zaderej Karen L.Director | Buy | 10,600 | 52K USD |
2 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 20 Aug 2026 | Elston GeorgeChief Financial Officer | Other | 10,000 | |
| 20 Aug 2026 | Elston GeorgeChief Financial Officer | Gift | 129,906 |
Which funds hold EyePoint Pharmaceuticals (EYPT)?
7 of the 45 institutional funds we track reported a EyePoint Pharmaceuticals position for the quarter ended 30 Jun 2026 — a combined 79.5M USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Citadel Advisors | Held (±25%) | 1,977,610 | 28.3M USD | +3.8% |
| Balyasny Asset Management | Added | 1,812,358 | 25.9M USD | +26.0% |
| Two Sigma Investments | Added | 1,181,143 | 16.9M USD | +174.5% |
| Millennium Management | Held (±25%) | 500,093 | 7.2M USD | +5.2% |
| Point72 Asset Management | New position | 48,574 | 695K USD | |
| Marshall Wace | Trimmed | 23,934 | 342K USD | −85.2% |
| Tudor Investment Corp | New position | 16,749 | 240K USD | |
| AQR Capital Management | Exited | |||
| Renaissance Technologies | Exited |
What has been filed or recorded for EyePoint Pharmaceuticals (EYPT)?
The filings we hold for EyePoint Pharmaceuticals, newest first: 2 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 14 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 14 Oct 2026 | Fails to deliver | Shares failed to deliver | 3,332 shares | 10K USD notional · 0.004% of shares out |
| 08 Oct 2026 | Fails to deliver | Shares failed to deliver | 4,480 shares | 15K USD notional · 0.005% of shares out |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −1.09 USD | |
| 30 Jun 2026 | Financials | Total assets | 228.2M USD | at period end |
| 30 Jun 2026 | Financials | Total equity | 166.4M USD | at period end |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.99 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −3.17 USD | |
| 31 Dec 2025 | Financials | Revenue | 31.4M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −232.0M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −3.17 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.85 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.85 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.65 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −2.32 USD | |
| 30 Sep 2024 | Quarterly earnings | Q3 2024 reported | EPS −0.54 USD |
What do people ask about EyePoint Pharmaceuticals (EYPT)?
What did EyePoint Pharmaceuticals shares close at?4.00
EyePoint Pharmaceuticals closed at 4.00 USD on 18 Sep 2026, up 0.13% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is EyePoint Pharmaceuticals’ market cap?344.8M
EyePoint Pharmaceuticals is worth 344.8M USD by market value as of 18 Sep 2026, which is the share price times the shares on issue from its SEC filings.
What is EyePoint Pharmaceuticals’ revenue?31.4M
EyePoint Pharmaceuticals reported revenue of 31.4M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have EyePoint Pharmaceuticals insiders bought or sold shares recently?1 purchase
In the 90 days to 11 Nov 2026, EyePoint Pharmaceuticals insiders reported 1 open-market purchase and no sales (SEC Form 4). A further 2 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own EyePoint Pharmaceuticals?7 of 45
7 of the 45 funds we track reported a EyePoint Pharmaceuticals position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Citadel Advisors, Balyasny Asset Management and Two Sigma Investments. See Funds
When did EyePoint Pharmaceuticals last report earnings?−1.09
EyePoint Pharmaceuticals last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −1.09 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Jun 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings